News
HanchorBio Advances Toward TWSE Innovation Board Listing to Accelerate Global Clinical Development, Platform Expansion, and International Partnering
HanchorBio, Inc., a global clinical-stage biotechnology company advancing next-generation multifunctional biologics across oncology and immune-related diseases, today announced that it has received approval from the Board of Directors of the Taiwan Stock Exchange to list on the TWSE Innovation Board, with listing anticipated in the second quarter of 2026, subject to completion of the remaining customary procedures.
Mar 24, 2026
Read more
HanchorBio Presents First Dedicated HCB101 Head and Neck Cancer Data in Oral Presentation at ICHNO 2026
HanchorBio announced the first dedicated presentation of HCB101 clinical data in head and neck squamous cell carcinoma (HNSCC) in an oral presentation at ICHNO 2026 (the 10th International Congress on Innovative Approaches in Head and Neck Oncology), a joint ESTRO, EHNS, and ESMO congress, in Seville, Spain.
Mar 20, 2026
Read more
HanchorBio Expands Global Patent Protection for HCB101 with Taiwan Grant
Taiwan grant adds to issued patents in the United States and Japan, further strengthening HCB101’s cross-border IP estate and supporting long-term development and partnering strategy.
Mar 17, 2026
Read more
HanchorBio Presents First Public Clinical Data for HCB301, a Tri-Specific Innate Checkpoint Molecule, at ESMO-TAT 2026
HanchorBio, Inc. announced the presentation of first-in-human clinical data for HCB301 at the ESMO Targeted Anticancer Therapies (TAT) Congress 2026 in Paris, France.
Mar 16, 2026
Read more
HanchorBio Highlights Advancing HCB101 Clinical Program Across Monotherapy and Combination Settings at ESMO-TAT 2026
HanchorBio announced the presentation of updated clinical data for HCB101 at the ESMO Targeted Anticancer Therapies (TAT) Congress 2026 in Paris, France.
Mar 16, 2026
Read more
Podcast Launch: Innovations in Immuno-Oncology
HanchorBio's new and original podcast series, Innovations in Immuno-Oncology, offer listeners a closer look at the scientific rationale, business strategy, and global licensing perspectives behind next-generation immuno-oncology drug development.
Mar 11, 2026
Read more
HanchorBio to Present Next-Generation Biologics Innovation at Biologics World Taiwan 2026
HanchorBio will participate in Biologics World Taiwan 2026, taking place on March 25–26, 2026, at Hilton Taipei Sinban, Taiwan. During the event, HanchorBio’s Chairman and Chief Executive Officer, Dr. Scott Liu, and Executive Director of CMC, Dr. Vivian Kuo, will be invited as speakers. They will share insights on next-generation biologics innovation, spanning immuno-oncology, tri-specific Fc fusion protein development, and process and CMC excellence for emerging drug modalities.
Mar 11, 2026
Read more
HanchorBio Presents Dose-Dependent Tumor Responses and Deepening Tumor Shrinkage with HCB101 Triple Combination in Second-Line Gastric Cancer at the 11th Asia-Pacific Gastroesophageal Cancer Congress
HanchorBio Presents Dose-Dependent Tumor Responses and Deepening Tumor Shrinkage with HCB101 Triple Combination in Second-Line Gastric Cancer at the 11th Asia-Pacific Gastroesophageal Cancer Congress Early clinical data show 100% ORR at 5.12 mg/kg, 100% DCR across doses, and dose-dependent tumor shrinkage; the 12 mg/kg cohort remains ongoing HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology […]
Mar 05, 2026
Read more
HanchorBio Founder Dr. Scott Liu Invited to Moderate at BIOCHINA 2026
BIOCHINA 2026 (11th BIOCHINA Annual Conference & Expo) will be held from March 12–14, 2026 in Suzhou, China. Dr. Scott Liu, Founder, Chairman and Chief Executive Officer of HanchorBio Inc., has been invited to attend the conference and will serve as a roundtable moderator at the Antibody Drug Innovation & Development Forum, as well as participate as a featured interview and discussion speaker.Interview Topic:
“Focused Strategies in Specialized Segments — Insights from BD Transactions on the Positioning and Collaborative Strategy of Bispecific and Multispecific Antibody Innovation”
Mar 02, 2026
Read more
HanchorBio Founder Dr. Scott Liu Invited to Moderate at BIOCHINA 2026
HanchorBio Founder Dr. Scott Liu Invited to Moderate at BIOCHINA 2026 BIOCHINA 2026 (11th BIOCHINA Annual Conference & Expo) will be held from March 12–14, 2026 in Suzhou, China. Dr. Scott Liu, Founder, Chairman and Chief Executive Officer of HanchorBio Inc., has been invited to attend the conference and will serve as a roundtable moderator at […]
Mar 02, 2026
Read more